ÇòʸĻ¥Ô¥Ômeʪ¸ì

¸¡»¡¤ÈÂç¼ê¥á¥Ç¥£¥¢¤ÎÌÀ¤é¤«¤ÊÈȺá

Á´ÂÎɽ¼¨

[ ¥ê¥¹¥È ]


¥Þ¥°¥Í¥·¥¦¥à¡§»Òáò¡¦ÊÒÆ¬ÄË¡¦Ó顦Ãí°Õ·ç´Ù¿ưÀ­¾ã³²Âкö¡¡2019/1/23

º£¡¢ÅìÆüËܤΡ¢¤½¤ì¤â£´£°ºÐÂ壵£°ºÐÂå¤ËµÞÁý¤·¤Æ¤¤¤ëÆÍÁ³»àÂкö¤È¤·¤ÆºÇ¤âÍ­¸ú¤Ê¥Þ¥°¥Í¥·¥¦¥à¤ò¼è¤ê¾å¤²¡¢º£¤Þ¤Ç°ÕÌõ¤·¤Æ¤­¤¿ÏÀʸ¤Ï¡¢¥Þ¥°¥Í¥·¥¦¥à¤Ë´Ø¤¹¤ëÀ¤³¦¤Î£±£´£¹¤Î¸¦µæÏÀʸ¤Î½¸ÌóÈǤǤ·¤¿¡£º£²ó¤Îµ­»ö¤¬¤½¤ÎºÇ½ª¾Ï¤Ç¤¹¡£

º£²ó¤â¤ä¤ä¤³¤·¤¤ÀìÌçÍѸ줬ÉÑÈˤËÅо줷¤Þ¤¹¤¬¡¢¤½¤ì¤é¤Ï̵»ë¤·¡¢·Ú¤¯ÆÉ¤ßή¤¹¤À¤±¤Ç³µÍפÏÇİ®¤Ç¤­¤ë¤Ç¤·¤ç¤¦¡£

¾°¡¢¿ä¾©¤µ¤ì¤ëƦÉå¤Ë»È¤ï¤ì¤Æ¤¤¤ë±ö²½¥Þ¥°¥Í¥·¥¦¥àÊ´Ëö¤ÎÀ®¿Í¤ÎÀݼèÎ̤ϡ¢Ãݤ쪤«¤­£³ÇÕ/Æü¤Ç¤¹¡£

¡ÊÁ°²óµ­»ö¡Ë
¡Ø¥Þ¥°¥Í¥·¥¦¥à¡§¹â·ì°µ¡¦¿´Â¡ÉÂÂкö¡Ù¡¡2019/1/21(·î) 


Pre-Eclampsia and Eclampsia
»Òáò¡Ê¤·¤«¤ó¡Ë¡ÊÃ𣱡ËÁ°¾É¤ª¤è¤Ó»Òáò

Pre-eclampsia or preeclampsia is a disorder of pregnancy characterized by hypertension, proteinuria, often accompanied by pathological oedema. 

»Òáò¡Ê¤·¤«¤ó¡ËÁ°¾É¤Þ¤¿¤ÏÇ¥¿±¹â·ì°µ¿Õ¾É¤Ï¡¢¤·¤Ð¤·¤ÐÉÂŪÉâ¼ð¤òȼ¤¦¹â·ì°µ¾É¡¢¥¿¥ó¥Ñ¥¯Ç¢¾É¤òÆÃħ¤È¤¹¤ëÇ¥¿±¾ã³²¤Ç¤¹¡£

¡ÊÃ𣱡˻Òáò¡Ê¤·¤«¤ó¡Ë
Ç¥¿±ÃæÆÇ¾É¤Î°ì¼ï¡£Ã»»þ´Ö¤ËÈ¿Éü¤¹¤ëÁ´¿È¤Î´ÖÂå(¤«¤ó¤À¤¤)À­áÛÚ»(¤±¤¤¤ì¤ó)ȯºî¡ÊáÛÚ»¡Ë¤òµ¯¤³¤·¡¤¼º¿À¤òȼ¤¦¡£Ç¥¿±»Òáò¡¤Ê¬ÊÚ(¤Ö¤ó¤Ù¤ó)»Òáò¡¤»ºêó(¤µ¤ó¤¸¤ç¤¯)»Òáò¤Ê¤É¤¬¤¢¤ë¡£

¸¶°ø¤Ë¤Ä¤¤¤Æ¤ÏÂÛÈס¦ÂÛ»ù¤«¤éÀ¸¤º¤ëÆÇÁǤ¬¡¤ÊìÂΤβòÆÇµ¡Ç½¤ÎÄã²¼¤Ë¤è¤ê¡¤¼«²ÈÃæÆÇ¤ò¤Ò¤­µ¯¤³¤¹¤Ê¤É³Æ¼ï¤ÎÀ⤬¤¢¤ë¡£Á°¶î¾É¾õ¡Ê»ÒáòÁ°¾É¡Ë¤È¤·¤Æ°ìÈ̤ËÉâ¼ð(¤Õ¤·¤å)¡¤¥¿¥ó¥Ñ¥¯Ç¢¡¤¹â·ì°µ¤òʻȯ¡¤Æ¬ÄË¡¤¤á¤Þ¤¤¡¤´ã¤Î¤Á¤é¤Ä¤­¡¤¼å»ë¡¤°ßÄË¡¤°­¿´(¤ª¤·¤ó)¤Ê¤É¤ò¼«³Ð¡£È¯ºî¤ÏÆÍÁ³°Õ¼±¤¬¾Ã¼º¡¤Á´¿È¤¬·ã¤·¤¯áÛÚ»¤·¡¤´éÌÌÁóÇò(¤½¤¦¤Ï¤¯)¤«¤é¥Á¥¢¥Î¡¼¥¼¤òÄ褷¡¤³«¸ýÉÔǽ¤È¤Ê¤êË¢(¤¢¤ï)¤ò¤Õ¤¯¡£È¯ºî¤¬½ª¤ï¤ë¤Èºª¿ç(¤³¤ó¤¹¤¤)¾õÂ֤ˤʤ롣ËýÀ­¿Õ±ê¡¤»ëÎϾ㳲¤Ê¤É¸å°ä¾É¤¬µ¯¤³¤ê¤ä¤¹¤¤¡£¡ÊÉ´²Ê»öŵ¥Þ¥¤¥Ú¥Ç¥£¥¢¡Ë

If left untreated, it may result in seizures at which point it is known as eclampsia. This complex disorder is characterized by haemoconcentration, vasoconstriction with increased peripheral resistance and reductions in cardiac output, plasma volume and prostacyclin synthesis. 

̤¼£ÎŤΤޤޤˤµ¤ì¤ë¤Ê¤é¤Ð¡¢¤½¤ì¤¬»Òáò¡Ê¤·¤«¤ó¡Ë¤È¤·¤ÆÃΤé¤ì¤ë¤½¤Î»þÅÀ¤Çȯºî¤ò°ú¤­µ¯¤³¤¹¤«¤â¤·¤ì¤Þ¤»¤ó¡£

¤³¤ÎÊ£»¨¤Ê¼À´µ¤Ï¡¢·ì±ÕÇ»½Ì¡¢Ëö¾¿Äñ¹³¤ÎÁý²Ã¤òȼ¤¦·ì´É¼ý½Ì¤ª¤è¤Ó¿´Çï½ÐÎ̤θº¾¯¡¢·ìÞùÎ̤ª¤è¤Ó¥×¥í¥¹¥¿¥µ¥¤¥¯¥ê¥ó¡ÊÃ𣲡˹çÀ®¤Ë¤è¤Ã¤ÆÆÃħÉÕ¤±¤é¤ì¤Þ¤¹¡£

¡ÊÃð£²¡Ë¥×¥í¥¹¥¿¥µ¥¤¥¯¥ê¥ó
¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥ó¤Î°ì¼ï¡£¥×¥í¥¹¥¿¥°¥é¥ó¥¸¥óI2¡£ÌÓºÙ·ì´É¤«¤éʬÈ礵¤ì·ì¾®ÈĤζŽ¸¤òËɻߤ·¡¢·ì´É¤ò³ÈÄ¥¤¹¤ë¹³·ìÀòºîÍѤ¬¤¢¤ë¡£

Up until today, magnesium sulfate has remained the most frequently used agent in the management of pre-eclampsia and eclampsia. 
Magnesium is the drug of choice to prevent convulsions in eclampsia . In the Magpie trial, women (n = 5071) allocated magnesium sulfate had a 58% lower risk of eclampsia (95% CI 40–71) than those allocated placebo (n = 5070) . 

º£Æü¤Þ¤Ç¡¢Î²»À¥Þ¥°¥Í¥·¥¦¥à¤Ï»Òáò¡Ê¤·¤«¤ó¡ËÁ°¾É¤ª¤è¤Ó»Òáò¤Î´ÉÍý¤Ë¤ª¤¤¤Æ°ÍÁ³¤ÈºÇ¤âÉÑÈˤ˻ÈÍѤµ¤ì¤ëÌôºÞ¤Ç¤·¤¿¡£

¥Þ¥°¥Í¥·¥¦¥à¤Ï»Òáò¤ÎáÛÚ»¤òͽËɤ¹¤ë¤Î¤ËºÇŬ¤ÊÌô¤Ç¤¹¡£ Magpie»î¸³¡ÊÃ𣳡ˤǤϡ¢Î²»À¥Þ¥°¥Í¥·¥¦¥à¤òÅêÍ¿¤µ¤ì¤¿½÷À­¡Ên = 5071¡Ë¤Ï¡¢¥×¥é¥»¥Ü¡Êµ¶Ìô¡Ë¤òÅêÍ¿¤µ¤ì¤¿½÷À­¡Ên = 5070¡Ë¤è¤ê¤â»Òáò¤Î¥ê¥¹¥¯¤¬58¡óÄ㤫¤Ã¤¿¡Ê95¡óCI 40〜71¡Ë¡£

¡ÊÃ𣳡ËMagpie»î¸³
»ÒáòÁ°¾É¤ËÂФ¹¤ëβ»À¥Þ¥°¥Í¥·¥¦¥à¤È¥×¥é¥»¥Ü¡Êµ¶Ìô¡Ë¤ÎÈæ³Ó̵ºî°Ù»î¸³

The specific mechanisms of action remain are unclear, the effects of magnesium sulfate in the prevention of eclampsia are likely multi-factorial. Magnesium sulfate may act as a vasodilator, with actions in the peripheral vasculature or the cerebral vasculature, to decrease peripheral vascular resistance or relieve vasoconstriction. Additionally, magnesium sulfate may also protect the blood–brain barrier and limit cerebral edema formation, or it may act through a central anticonvulsant action . Notably, nimodipine, a selective cerebral vasodilator, and also the antiepileptic phenytoine were not found to be as effective in eclampsia as magnesium

¶ñÂÎŪ¤ÊºîÍѵ¡½ø¤Ï°ÍÁ³¤È¤·¤ÆÉÔÌÀ¤Ç¤¢¤ê¡¢»Òáò¤ÎͽËɤˤª¤±¤ëβ»À¥Þ¥°¥Í¥·¥¦¥à¤Î¸ú²Ì¤Ï¿°ø»ÒÀ­¡ÊÃ𣴡ˤǤ¢¤ë²ÄǽÀ­¤¬¹â¤¤¡£

¡ÊÃ𣴡Ë¿°ø»ÒÀ­
´Ä¶­°ø»Ò¤À¤±¤Ç¤Ê¤¯¡¤°äÅÁÍ×°ø¤â¿¼¤¯´Ø·¸¤¹¤ë

β»À¥Þ¥°¥Í¥·¥¦¥à¤Ï¡¢Ëö¾¿·ì´É·Ï¤Þ¤¿¤ÏǾ·ì´É·Ï¤Ë¤ª¤±¤ëºîÍѤȶ¦¤Ë·ì´É³ÈÄ¥ºÞ¤È¤·¤ÆºîÍѤ·¡¢Ëö¾¿·ì´ÉÄñ¹³¤òÄã²¼¤µ¤»¤ë¤«¤Þ¤¿¤Ï·ì´É¼ý½Ì¤ò·Ú¸º¤¹¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

¤µ¤é¤Ë¡¢Î²»À¥Þ¥°¥Í¥·¥¦¥à¤Ï·ì±ÕǾ¾ã³²¤òÊݸ¡¢Ç¾Éâ¼ð¤Î·ÁÀ®¤òÀ©¸Â¤¹¤ë²ÄǽÀ­¤¬¤¢¤ê¤Þ¤¹¡£¤¢¤ë¤¤¤Ï¤½¤ì¤Ï¼çÍפʤ±¤¤¤ì¤ó»ß¤á¤òÄ̤·¤ÆºîÍѤ¹¤ë¤Î¤«¤â¤·¤ì¤Þ¤»¤ó¡£

ÆÃ¤Ë¡¢¥Ë¥â¥¸¥Ô¥ó¡ÊÃ𣵡ˡ¢ÁªÂòŪǾ·ì´É³ÈÄ¥Ìô¡¢¤½¤·¤Æ¤Þ¤¿¹³¤Æ¤ó¤«¤óÀ­¡ÊÃ𣶡˥ե§¥Ë¥È¥¤¥ó¤â¡¢»Òáò¤Ë¥Þ¥°¥Í¥·¥¦¥à¤ÈƱ¤¸¤¯¤é¤¤¸ú²ÌŪ¤Ç¤¢¤ë¤³¤È¤¬¤ï¤«¤Ã¤Æ¤¤¤Þ¤»¤ó¤Ç¤·¤¿¡£¡ÊÃí¡Ëβ»À¥Þ¥°¥Í¥·¥¦¥à¤ÎÊý¤¬Í­¸ú¤Ç¤¢¤ë¤È¤¤¤¦¤³¤È¡£

¡ÊÃ𣵡˥˥⥸¥Ô¥ó
ÆÃ°ÛŪ¤ÊǾ·ì´É³ÈÄ¥³èÀ­¤ò¤â¤Ä¥«¥ë¥·¥¦¥àÙɹ³Ìô¡ÊºÙ˦Æâ¤Ø¤Î¥«¥ë¥·¥¦¥à¥¤¥ª¥ó¤ÎήÆþ¤òÍÞÀ©¤¹¤ëÌô¡Ë¡£

¡ÊÃ𣶡˥ե§¥Ë¥È¥¤¥ó
¹³¤Æ¤ó¤«¤óºÞ¡£Ç¾¤ÎÃæ¿õ¤ËºîÍѤ·¤Æ¤±¤¤¤ì¤ó¤òÍÞÀ©¤¹¤ë¤Î¤Ç¡¢¤Æ¤ó¤«¤ó¤Î¤±¤¤¤ì¤óȯºî¤òÍÞ¤¨¤ë¡£


Migraine Headaches
ÊÒÆ¬ÄË

Studies have found that patients with cluster headaches and classic or common migraine, especially menstrual migraine, have low levels of magnesium . In order to evaluate the prophylactic effect of oral magnesium, 81 patients aged 18–65 years with migraine according to the International Headache Society criteria (mean attack frequency 3.6 per month) were examined . 
After a prospective baseline period of 4 weeks they received oral 600 mg (24 mmol) magnesium (trimagnesium dicitrate) daily for 12 weeks or placebo. In weeks 9–12 the attack frequency was reduced by 41.6% in the magnesium group and by 15.8% in the placebo group compared to the baseline (p < 0.05). 

¸¦µæ¤Ë¤è¤ê¡¢·²È¯À­Æ¬Äˤª¤è¤Ó¸ÅŵŪ¤Þ¤¿¤Ï°ìÈÌŪ¤ÊÊÒÆ¬ÄË¡¢ÆÃ¤Ë·î·ÐÀ­ÊÒÆ¬ÄˤòÍ­¤¹¤ë´µ¼Ô¤Ï¥Þ¥°¥Í¥·¥¦¥à¤¬Äã¥ì¥Ù¥ë¤Ç¤¢¤ë¤³¤È¤¬¸«¤¤¤À¤µ¤ì¤Þ¤·¤¿¡£

·Ð¸ý¥Þ¥°¥Í¥·¥¦¥à¤ÎͽËɸú²Ì¤òɾ²Á¤¹¤ë¤¿¤á¤Ë¡¢¹ñºÝƬÄ˳زñ¤Î´ð½à¡Ê·î¤¢¤¿¤ê¤ÎÊ¿¶ÑȯºîÉÑÅÙ3.6¡Ë¤Ë½¾¤Ã¤ÆÊÒÆ¬ÄˤòÍ­¤¹¤ë18〜65ºÐ¤Î81¿Í¤Î´µ¼Ô¤òÄ´¤Ù¤Þ¤·¤¿¡£

ͽÁÛ¤µ¤ì¤ë´ð½àÃÍ4½µ´Ö¤Î´ü´Ö¤Î¸å¡¢Èà¤é¤Ï·Ð¸ý¤Ç600mg¡Ê24mmol¡Ë¤Î¥Þ¥°¥Í¥·¥¦¥à¡ÊÆó¥Þ¥°¥Í¥·¥¦¥à¥¸¥·¥È¥ì¡¼¥È¡Ë¤ò12½µ´Ö¤Þ¤¿¤Ï¥×¥é¥»¥Ü¡Êµ¶Ìô¡Ë¤òÅêÍ¿¤µ¤ì¤Þ¤·¤¿¡£ 9〜12½µÌܤˡ¢È¯ºîÉÑÅ٤ϥ١¼¥¹¥é¥¤¥ó¤ÈÈæ³Ó¤·¤Æ¥Þ¥°¥Í¥·¥¦¥à·²¤Ç41.6¡ó¡¢¥×¥é¥»¥Ü·²¤Ç15.8¡ó¸º¾¯¤·¤Þ¤·¤¿¡Êp <0.05¡Ë¡£

 In weeks 9–12 the attack frequency was reduced by 41.6% in the magnesium group and by 15.8% in the placebo group compared to the baseline (p < 0.05). The number of days with migraine and the drug consumption for symptomatic treatment per patient also decreased significantly in the magnesium group .

9〜12½µÌܤˡ¢È¯ºîÉÑÅ٤ϴð½àÃͤÈÈæ³Ó¤·¤Æ¥Þ¥°¥Í¥·¥¦¥à·²¤Ç41.6¡ó¡¢¥×¥é¥»¥Ü¡Êµ¶Ìô¡Ë·²¤Ç15.8¡ó¸º¾¯¤·¤Þ¤·¤¿¡Êp <0.05¡Ë¡£

ÊÒÆ¬Äˤòȼ¤¦Æü¿ô¤ª¤è¤Ó´µ¼Ô¤¢¤¿¤ê¤ÎÂоÉÎÅË¡¤Î¤¿¤á¤ÎÌôʪ¾ÃÈñÎ̤â¥Þ¥°¥Í¥·¥¦¥à·²¤ÇÍ­°Õ¤Ë¸º¾¯¤·¤Þ¤·¤¿¡£

For acute treatment of migraine, intravenous magnesium sulfate (1000 mg magnesium intravenously) showed a statistically significant improvement in the treatment of all symptoms in patients with aura, or as an adjuvant therapy for associated symptoms in patients without aura . According to recent studies, magnesium sulfate is as effective and a fast-acting medication compared to a combination of dexamethasone/metoclopramide for the treatment of acute migraine headaches .

ÊÒÆ¬ÄˤεÞÀ­¼£ÎŤǤϡ¢Î²»À¥Þ¥°¥Í¥·¥¦¥à¤ÎÀÅÌ®ÆâÅêÍ¿¡Ê1000mg¤Î¥Þ¥°¥Í¥·¥¦¥à¤ÎÀÅÌ®ÆâÅêÍ¿¡Ë¤Ï¡¢Á°Ãû¤Î¤¢¤ë´µ¼Ô¤ÎÁ´¤Æ¤Î¾É¾õ¤Î¼£ÎŤˤª¤¤¤Æ¡¢¤Þ¤¿¤ÏÁ°Ãû¤Î¤Ê¤¤´µ¼Ô¤Î´ØÏ¢¾É¾õ¤ËÂФ¹¤ëÊä½õÎÅË¡¤È¤·¤ÆÅý·×Ū¤ËÍ­°Õ¤Ê²þÁ±¤ò¼¨¤·¤Þ¤·¤¿¡£

ºÇ¶á¤Î¸¦µæ¤Ë¤è¤ì¤Ð¡¢Î²»À¥Þ¥°¥Í¥·¥¦¥à¤ÏµÞÀ­ÊÒÆ¬Äˤμ£ÎŤΤ¿¤á¤Î¥Ç¥­¥µ¥á¥¿¥¾¥ó/¥á¥È¥¯¥í¥×¥é¥ß¥É¤ÎÁȤ߹ç¤ï¤»¡ÊÃ𣷡ˤÈÈæ³Ó¤·¤ÆÆ±¤¸¤¯¤é¤¤¸ú²ÌŪ¤Ç¨¸úÀ­¤ÎÌô¤Ç¤¹¡£

¡ÊÃ𣷡˥ǥ­¥µ¥á¥¿¥¾¥ó/¥á¥È¥¯¥í¥×¥é¥ß¥É¤ÎÁȤ߹ç¤ï¤»
¤³¤ÎÆó¼ï¤ÎÌôºÞ¤ÎÊ»ÍÑÎÅË¡¤ÇÓÒµ¤¡Ê¤ª¤¦¤­¡¢ÅǤ­µ¤¡Ë¡¦ÓÒÅǡʤª¤¦¤È¡Ë¤òÍÞÀ©¤¹¤ëºîÍѤò¤â¤Ä¡£


ADHD
Ãí°Õ·ç´Ù¿ưÀ­¾ã³²¡ÊÃ𣸡Ë

¡ÊÃ𣸡ËÃí°Õ·ç´Ù¿ưÀ­¾ã³²
¼«Ê¬¤ò¥³¥ó¥È¥í¡¼¥ë¤¹¤ëÎϤ¬¼å¤¯¡¢¤½¤ì¤¬¹ÔưÌ̤ÎÌäÂê¤È¤Ê¤Ã¤Æ¤¢¤é¤ï¤ì¤ë¾ã³²¡£ÉÔÃí°Õ¡Ê½¸ÃæÎϤ¬¤Ê¤¤¡¦µ¤¤¬»¶¤ê¤ä¤¹¤¤¡Ë¡¢Â¿Æ°À­¡Ê¤¸¤Ã¤È¤·¤Æ¤¤¤é¤ì¤Ê¤¤¡¦Íî¤ÁÃ夭¤¬¤Ê¤¤¡Ë¡¢¾×ưÀ­ ¡Ê½çÈÖ¤òÂԤƤʤ¤¡¦¹Í¤¨¤ëÁ°¤Ë¼Â¹Ô¤·¤Æ¤·¤Þ¤¦¡Ë¤Î3¤Ä¤ÎÍ×ÁǤ¬¤ß¤é¤ì¤ëȯã¾ã³²¤Î¤Ò¤È¤Ä¡£

Attention deficit hyperactivity disorder (ADHD) is the most common psychiatric disorder in clinical samples of children and adolescents referring to child psychiatric clinics. Dietary factors can play a significant role in the etiology of attention deficit hyperactivity disorder (ADHD). Several studies reported that the magnesium level in children with ADHD is decreased in serum and erythrocytes and the Mg2+-ATPase activity is reduced . 

»ùƸÀº¿À²Ê¥¯¥ê¥Ë¥Ã¥¯¤ò¸«¤ë¤È¾®»ù¤ª¤è¤Ó»×½Õ´ü¤ÎÎ×¾²¥µ¥ó¥×¥ëÃæ¡¢Ãí°Õ·ç´Ù¿ưÀ­¾ã³²¡ÊADHD¡Ë¤ÏºÇ¤â°ìÈÌŪ¤ÊÀº¿À¾ã³²¤Ç¤¹¡£

¿©»öÍ×°ø¤ÏÃí°Õ·ç´Ù¿ưÀ­¾ã³²¡ÊADHD¡Ë¤Îɰø¤Ë½ÅÍפÊÌò³ä¤ò²Ì¤¿¤¹¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£¤¤¤¯¤Ä¤«¤Î¸¦µæ¤Ç¤Ï¡¢ADHD¤Î¾®»ù¤Î¥Þ¥°¥Í¥·¥¦¥à¥ì¥Ù¥ë¤¬·ìÀ¶¤ÈÀÖ·ìµå¤Ç¸º¾¯¤·¡¢¤½¤·¤ÆMg 2+ -ATPase¡ÊÃ𣹡˳èÀ­¤¬¸º¾¯¤¹¤ë¤³¤È¤òÊó¹ð¤·¤Þ¤·¤¿¡£

¡ÊÃ𣹡ËATPase¡ÊATP¥¢¡¼¥¼¡Ë
¥¢¥Ç¥Î¥·¥ó»°¥ê¥ó»À (ATP) ¤ÎËöü¹â¥¨¥Í¥ë¥®¡¼¥ê¥ó»À·ë¹ç¤ò²Ã¿åʬ²ò¤¹¤ë¹ÚÁÇ·²¤ÎÁí¾Î¡£¥¢¥Ç¥Î¥·¥ó»°¥ê¥ó»À¡ÊATP¡Ë¢ª¡¡¥¢¥Ç¥Î¥·¥óÆó¥ê¥ó»À¡ÊADP¡Ë + ¥ê¥ó»À ¡ÊP¡Ë
ATP¥¢¡¼¥¼¤ÎÌò³ä¤Ï¥¨¥Í¥ë¥®¡¼¤Î´ØÍ¿¤¹¤ëÁ´¤Æ¤ÎÈ¿±þ¤Ë´óÍ¿¤·¤Æ¤¤¤ë¤È¸À¤Ã¤Æ¤è¤¤¡£

Treatment of magnesium deficiency can help in revealing hyperactivity in children . Current treatments for ADHD, such as atomoxetine and stimulants, act through adrenergic and dopaminergic receptors. Magnesium interacts with the ADHD-related neurotransmitters (e.g., dopamine, serotonin) and inhibits N-methyl-d-aspartate (NMDA)-induced norepinephrine release. 

¥Þ¥°¥Í¥·¥¦¥à·ç˳¾É¤Î¼£ÎŤϡ¢»Ò¶¡¤Î¿ưÀ­¡Ê²á¾ê³èư¡Ë¤òÌÀ¤é¤«¤Ë¤¹¤ë¤Î¤ËÌòΩ¤Á¤Þ¤¹¡£¡Ê°Ê²¼¡¢¤³¤³¤Î¹àÌܤΰÕÌõ¾Êά¡Ë

The results of several studies are promising that magnesium supplementation (e.g. 6 mg/kg BW per day) may be helpful in the treatment of ADHD . Unfortunately, until now there is still no double-blind randomized controlled clinical trial investigating the efficacy and safety of magnesium for treating ADHD.

¤¤¤¯¤Ä¤«¤Î¸¦µæ¤Î·ë²Ì¤Ï¡¢¥Þ¥°¥Í¥·¥¦¥àÊäµë¡ÊÎ㤨¤Ð¡¢£±ÆüÅö¤¿¤ê£¶£í£ç ¡¿ £ë£ç £Â£×¡Ë¤¬£Á£Ä£È£Ä¤Î¼£ÎŤËÍ­ÍѤǤ¢¤êÆÀ¤ë¤³¤È¤òÌ󫤷¤Æ¤¤¤Þ¤¹¡£

»Äǰ¤Ê¤¬¤é¡¢¤³¤ì¤Þ¤Ç¤Î¤È¤³¤í¡¢ADHD¤ò¼£ÎŤ¹¤ë¤¿¤á¤Î¥Þ¥°¥Í¥·¥¦¥à¤ÎÍ­¸úÀ­¤È°ÂÁ´À­¤òÄ´ºº¤¹¤ë¥À¥Ö¥ë¡¦¥Ö¥é¥¤¥ó¥É¡¦¥Æ¥¹¥È¡ÊÃ𣱣°¡Ë¤Ï¤Þ¤À¤¢¤ê¤Þ¤»¤ó¡£

¡ÊÃ𣱣°¡Ë¥À¥Ö¥ë¡¦¥Ö¥é¥¤¥ó¥É¡¦¥Æ¥¹¥È
»î¸³¥Ç¥¶¥¤¥ó¤Î°ì¼ï¤Ç¡¢¼£¸³¼Â»Ü¤Ë´Ø¤ï¤ë¤¹¤Ù¤Æ¤Î¿Í´Ö¤¬¡¢¤É¤ó¤ÊÌô¤òÅêÍ¿¤¹¤ë¤Î¤«°ìÀÚÃΤ餺¤Ë¹Ô¤ï¤ì¤ë¼£¸³ÊýË¡¡£ 

¿·Ìô¡ÊÈ︳Ìô¡Ë¤Î¼£ÎŸú²Ì¡¦Í­¸úÀ­¤ò³Î¤«¤á¤ë¤¿¤á¤ÎÈæ³Ó»î¸³¤È¤·¤ÆºÇ¤â°ìÈÌŪ¤ÊÊýË¡¤Ç¤¢¤ê¡¢Æó½ÅÌÕ¸¡Èæ³Ó»î¸³¡¢DBT¤È¤â¤¤¤ï¤ì¤ë¡£ ¥À¥Ö¥ë¡¦¥Ö¥é¥¤¥ó¥É¡¦¥Æ¥¹¥È¤Ï¡¢¼£¸³¤ÎÈ︳¼Ô·²¤òA·²¤ÈB·²¤ËÆóʬ¤·¡¢A·²¤Ë¤ÏÈ︳Ìô¤ò¡¢B·²¤Ë¤ÏÂоÈÌô¡Ê¥×¥é¥»¥Ü¤Ê¤É¡Ë¤òÅêÍ¿¤·¤ÆÈæ³Ó¤ò¹Ô¤¦¡£¥À¥Ö¥ë¡¦¥Ö¥é¥¤¥ó¥É¡¦¥Æ¥¹¥È¤ÎÆÃħ¤Ï¡¢¤É¤Á¤é¤Î¥°¥ë¡¼¥×¤Ë¤É¤Á¤é¤ÎÌô¤òÅêÍ¿¤·¤Æ¤¤¤ë¤«¡¢Ã¯¤âÃΤé¤Ê¤¤ÅÀ¤Ë¤¢¤ë¡£


Alzheimer¡Çs Disease
¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼ÉÂ

Alzheimer¡Çs disease (AD) is the most widespread reason for dementia. AD is characterized by profound synapse loss and impairments of learning and memory. Recent studies have demonstrated that the brain, serum and ionized magnesium levels are decreased in AD patients; however, the exact role of magnesium in AD pathogenesis remains unclear.

¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¡ÊAD¡Ë¤¬Ç§ÃξɤκǤ⹭ÈϤʸ¶°ø¤Ç¤¹¡£ £Á£Ä¤Ï¡¢¿¼¹ï¤Ê¥·¥Ê¥×¥¹¡Ê¿À·ÐÅÁãʪ¼Á¡Ë¡ÊÃ𣱣±¡ËÁÓ¼º¤Ê¤é¤Ó¤Ë³Ø½¬¤ª¤è¤Óµ­²±¤Î¾ã³²¤Ë¤è¤Ã¤ÆÆÃħÉÕ¤±¤é¤ì¤Þ¤¹¡£ºÇ¶á¤Î¸¦µæ¤Ï¡¢Ç¾¡¢·ìÀ¶¤ª¤è¤Ó¥¤¥ª¥ó²½¥Þ¥°¥Í¥·¥¦¥à¤Î¥ì¥Ù¥ë¤¬AD´µ¼Ô¤Ë¤ª¤¤¤Æ¸º¾¯¤¹¤ë¤³¤È¤ò¼¨¤·¤Þ¤·¤¿¡£Ã¢¤·¡¢AD¤Îɰø¤Ë¤ª¤±¤ë¥Þ¥°¥Í¥·¥¦¥à¤ÎÀµ³Î¤ÊÌò³ä¤ÏÉÔÌÀ¤Ç¤¹¡£

¡ÊÃ𣱣±¡Ë¥·¥Ê¥×¥¹¡Ê¿À·ÐÅÁãʪ¼Á¡Ë
¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼¤äǧÃξɤΥᥫ¥Ë¥º¥à

 In mice a chronic reduction in dietary magnesium impairs memory , and the treatment of dementia patients with nutritional magnesium improves memory . 
Magnesium depletion, particularly in the hippocampus, appears to represent an important pathogenic factor in AD . Magnesium affects many biochemical mechanisms that are vital for neuronal properties and synaptic plasticity. 

¥Þ¥¦¥¹¤Ç¤Ï¡¢¿©¤Ùʪ¤Ç¤Î¥Þ¥°¥Í¥·¥¦¥à¤ÎËýÀ­Åª¤Ê¸º¾¯¤Ïµ­²±¤ò»¤Ê¤¤¡¢±ÉÍܤȤ·¤Æ¤Î¥Þ¥°¥Í¥·¥¦¥à¤Ë¤è¤ëǧÃξɴµ¼Ô¤Î¼£ÎŤϵ­²±¤ò²þÁ±¤·¤Þ¤¹¡£

ÆÃ¤Ë³¤ÇϤˤª¤±¤ë¥Þ¥°¥Í¥·¥¦¥à¤Î¸Ï³é¤Ï¡¢AD¤Ë¤ª¤±¤ë½ÅÍפÊɸ¶°ø»Ò¤òɽ¤¹¤È»×¤ï¤ì¤Þ¤¹¡£ ¥Þ¥°¥Í¥·¥¦¥à¤Ï¡¢ Ç¾¿À·ÐºÙ˦¥Ë¥å¡¼¥í¥ó¤ÎÀ­¼Á¤È¥·¥Ê¥×¥¹²ÄÁºÀ­¤ËÉԲķç¤Ê¿¤¯¤ÎÀ¸²½³ØÅª¥á¥«¥Ë¥º¥à¤Ë±Æ¶Á¤òÍ¿¤¨¤Þ¤¹¡£

Magnesium treatment reduced A¦Â plaque and prevented synapse loss and memory decline in a transgenic mouse model of AD . A decreased magnesium level is found in various tissues of AD patients in clinical and laboratory studies . New findings in animal studies are promising and provide novel insights in the neuroprotective effects of magnesium suggesting that magnesium treatment at the early stage may decrease the risk for cognitive decline in AD .

¥Þ¥°¥Í¥·¥¦¥à¼£ÎŤϡ¢AD¤Î°äÅÁ»ÒƳÆþ¥â¥Ç¥ë¤Ë¤ª¤¤¤ÆA¦ÂÈáÊÃ𣱣²¡Ë¤ò¸º¾¯¤µ¤»¡¢¥·¥Ê¥×¥¹¾Ã¼º¤ª¤è¤Óµ­²±¿êÂà¤òͽËɤ·¤Þ¤·¤¿¡£

¡ÊÃ𣱣²¡ËA¦ÂÈÃ
A¦Â¤Ï¥¢¥ß¥í¥¤¥É¦ÂÃÁÇò(A¦Â)¤Ï¥¢¥ß¥Î»À¤«¤é¤Ê¤ë¥Ú¥×¥Á¥É¡£¿À·ÐºÙ˦ÆÇÀ­¤Î¶¯¤¤A¦ÂÃÁÇò¤¬¿À·ÐºÙ˦³°¤ËÄÀÃ夷¤¿¤â¤Î¤¬A¦ÂÈÃËô¤ÏÏ·¿ÍÈá£

Î×¾²Åª¤ª¤è¤Ó¼Â¸³Åª¸¦µæ¤Ë¤ª¤¤¤Æ¡¢¥Þ¥°¥Í¥·¥¦¥à¥ì¥Ù¥ë¤ÎÄã²¼¤¬AD´µ¼Ô¤Î¤µ¤Þ¤¶¤Þ¤ÊÁÈ¿¥¤Ë¸«¤é¤ì¤Þ¤¹¡£

ưʪ¼Â¸³¤Ç¤Î¿·¤·¤¤Ãθ«¡Ê¼ÂºÝ¤Ë¸«¤ÆÃΤ뤳¤È¡Ë¤Ïͭ˾¤Ç¤¢¤ê¡¢¥Þ¥°¥Í¥·¥¦¥à¤Î¿À·ÐÊݸî¸ú²Ì¤Ë¤Ä¤¤¤Æ¤Î¿·¤¿¤Êƶ»¡¤òÄ󶡤·¡¢Áá´üÃʳ¬¤Ç¤Î¥Þ¥°¥Í¥·¥¦¥à¼£ÎŤÏAD¤ÎǧÃε¡Ç½Äã²¼¤Î¥ê¥¹¥¯¤ò¸º¤é¤¹²ÄǽÀ­¤¬¤¢¤ë¤³¤È¤ò¼¨º¶¤·¤Æ¤¤¤Þ¤¹¡£


Asthma
Óé

Several clinical trials examined the effect of intravenous magnesium infusions on acute asthma attacks. A double-blind placebo-controlled trial in 38 adults who did not respond to initial treatment (beta agonist) in the emergency room found improved lung function and decreased likelihood of hospitalization when magnesium sulfate (1.2 g of magnesium sulfate) was infused compared with a placebo. 

¤¤¤¯¤Ä¤«¤ÎÎ×¾²»î¸³¤Ï¡¢µÞÀ­Óéȯºî¤ËÂФ¹¤ëÀÅÌ®Æâ¥Þ¥°¥Í¥·¥¦¥àÃíÆþ¤Î¸ú²Ì¤òÄ´¤Ù¤Þ¤·¤¿¡£ ¶ÛµÞ¼£Îż¼¤Ç½é²ó¼£ÎŤËÈ¿±þ¤·¤Ê¤«¤Ã¤¿À®¿Í38¿Í¤òÂоݤȤ·¤¿Æó½ÅÌÕ¸¡¥×¥é¥»¥ÜÂоȻ¤Ç¤Ï¡¢Î²»À¥Þ¥°¥Í¥·¥¦¥à¡Ê1.2g¤Îβ»À¥Þ¥°¥Í¥·¥¦¥à¡Ë¤òÃíÆþ¤·¤¿¾ì¹ç¤ÈÈæ³Ó¤·¤ÆÇÙµ¡Ç½¤¬²þÁ±¤·Æþ±¡¤Î²ÄǽÀ­¤¬¸º¾¯¤·¤Þ¤·¤¿¡£¡Ê¤³¤Î¹à¡¢°Ê²¼¾Êά¡Ë

¡ÊÃæÎ¬¡Ë

Dosage and Supplements
ÅêÍ¿Î̤ȥµ¥×¥ê¥á¥ó¥È

Many nutritional experts feel the ideal intake for magnesium should be based on the body weight (e.g., 4–6 mg per kg/day). Magnesium supplements are available as magnesium oxide, magnesium chloride, magnesium citrate, magnesium taurate, magnesium orotate, as well as other amino acid chelates. In the treatment of magnesium deficiency we would recommend, because of their high bioavailability, organic bound magnesium salts, such as magnesium citrate, gluconate, orotate, or aspartate .

¿¤¯¤Î±ÉÍܳؤÎÀìÌç²È¤Ï¡¢¥Þ¥°¥Í¥·¥¦¥à¤ÎÍýÁÛŪ¤ÊÀݼèÎ̤ÏÂνŤ˴ð¤Å¤¤¤¿¤â¤Î¤Ç¤¢¤ë¤Ù¤­¤À¤È¹Í¤¨¤Æ¤¤¤Þ¤¹¡ÊÎã¡¢1kg /Æü¤¢¤¿¤ê4〜6mg¡Ë¡ÊÃ𣱣³¡Ë¡£

 ¥Þ¥°¥Í¥·¥¦¥à¥µ¥×¥ê¥á¥ó¥È¤Ï¡¢»À²½¥Þ¥°¥Í¥·¥¦¥à¡¢±ö²½¥Þ¥°¥Í¥·¥¦¥à¡¢¥¯¥¨¥ó»À¥Þ¥°¥Í¥·¥¦¥à¡¢¥¿¥¦»À¥Þ¥°¥Í¥·¥¦¥à¡¢¥ª¥í¥Á¥ó»À¥Þ¥°¥Í¥·¥¦¥à¡¢¤Ê¤é¤Ó¤Ë¾¤Î¥¢¥ß¥Î»À¥­¥ì¡¼¥È¤È¤·¤ÆÆþ¼ê²Äǽ¤Ç¤¹¡£ ¥Þ¥°¥Í¥·¥¦¥à·ç˳¾É¤Î¼£ÎŤˤϡ¢¤½¤ì¤é¤Î¹â¤¤À¸Êª³ØÅªÍøÍÑǽ¤Î¤¿¤á¤Ë¡¢¥¯¥¨¥ó»À¥Þ¥°¥Í¥·¥¦¥à¡¢¥°¥ë¥³¥ó»À±ö¡¢¥ª¥í¥Á¥ó»À±ö¡¢¤Þ¤¿¤Ï¥¢¥¹¥Ñ¥é¥®¥ó»À±ö¤Î¤è¤¦¤ÊÍ­µ¡·ë¹ç¥Þ¥°¥Í¥·¥¦¥à±ö¤¬¿ä¾©¤µ¤ì¤Þ¤¹¡£

¡ÊÃ𣱣³¡ËÂνÅ1kg /Æü¤¢¤¿¤ê4〜6mg¡ÊÊ¿¶Ñ5mg¡Ë

Âνţ´£°kg¤Î¾ì¹ç¤Ï¡¢£²£°£°mg/Æü¡¡¡Ê£°.£²g/Æü¡Ë¡¡¼ª¤«¤­£³.£²ÇÕ¡£
Âνţ¶£°kg¤Î¾ì¹ç¤Ï¡¢£³£°£°mg/Æü¡¡¡Ê£°.£³g/Æü¡Ë¡¡¼ª¤«¤­£´.£¸ÇÕ¡£

➀Ìܰ¤Ȥ·¤Æ¤Ï¡¢Âç¿Í°ì¿Íʬ¤ÏÃݤ쪤«¤­£³ÇÕ¶¯/Æü¤Ç¤¹¡£

¡Ê»»½Ð¡Ë¼ª¤«¤­°ìÇդϡ¢¿å¤Ê¤É¤ÎÈæ½Å£±¤Î¾ì¹ç¤Ï£²£·¥ß¥ê¥°¥é¥à¡¢27/1000cc¡£±ö²½¥Þ¥°¥Í¥·¥¦¥à¤ÏÈæ½Å£².£³£²¤À¤«¤é¡¢¼ª¤«¤­°ìÇդǣ¶£².£¶£´¥ß¥ê¥°¥é¥à¡£¡¡

②¤ª»ÒÍÍ£²¿Í¤Î²È²£´¿Í¤Î¾ì¹ç¡¢°ìÆü°ì²ó¡¢Î㤨¤Ð¡¢Í¼¿©¤ÎÌ£Á¹½Á¤Ë¼ª¤«¤­£·ÇÕ/Æü¡£

➂ÌîºÚ¥µ¥é¥À¤Ê¤É¤ËľÀÜ¿¶¤ê³Ý¤±¤¿¾ì¹ç¡¢¶ì¤ß¤Ç¤ª»ÒÍͤϷù¤¬¤ê¤Þ¤¹¡£
④°ìÅÙ³«Éõ¤·¤¿¤é¼¾µ¤¤òµÛ¤¤¤Þ¤¹¤«¤éľ¤°¤ËºÆÅÙÌ©ÊĤ·Êݴɤ¹¤ëɬÍפ¬¤¢¤ê¤Þ¤¹¡£¥³¥·¥ç¥¦¤Ê¤É¤ÎÍÆ´ï¤Ë¾®Ê¬¤±¤·¤¿¾ì¹ç¤Ç¤â¡¢¼¾µ¤¤ÇÌܵͤޤê¤òµ¯¤³¤·¤Þ¤¹¤«¤é¡¢´°Á´Ì©ÊĽÐÍè¤ë¥¸¥ã¥à¤Ê¤É¤Î¥¬¥é¥¹ÍÆ´ï¤Ë¾®Ê¬¤±¤·¤Æ»È¤¤¤Þ¤¹¡£
⑤ÄÌÈΤÎÌô¶É¤Ç¤Ï±ö²½¥Þ¥°¥Í¥·¥¦¥àÊ´Ëö£µ£°£°£ç£µ£°£°±ß¤Ç¤¹¡£
⑥Àݤꤹ¤®¤Ë¤ÏÃí°Õ¤·¤Þ¤·¤ç¤¦¡£
¡Ê»²¹Í¡Ë¾®¤µ¤¸£±ÇÕ¡¡£µcc¡¡£´g¡Ê£´£°£°£°mg¡Ë


Adverse Effects and Interactions
Í­³²ºîÍѤÈÁê¸ßºîÍÑ

Magnesium supplementation is well tolerated, but it can cause gastrointestinal symptoms, including diarrhea, nausea, and vomiting. An overdose of intravenous magnesium may cause thirst, hypotension, drowsiness, muscle weakness, respiratory depression, cardiac arrhythmia, coma, and death. 

¥Þ¥°¥Í¥·¥¦¥à¤ÎÊäµë¤Ï¤ª¤ª¤¶¤Ã¤Ñ¤Ç¤¤¤¤¤Ç¤¹¤¬¡¢²¼Î¡¡¢ÅǤ­µ¤¡¢ÓÒÅǤʤɤΰßIJ¾É¾õ¤ò°ú¤­µ¯¤³¤¹²ÄǽÀ­¤¬¤¢¤ê¤Þ¤¹¡£ ÀÅÌ®Æâ¥Þ¥°¥Í¥·¥¦¥à¤Î²á¾êÀݼè¤Ï¤Î¤É¤Î³é¤­¡¢Äã·ì°µ¡¢Ì²µ¤¡¢¶ÚÎÏÄã²¼¡¢¸ÆµÛÍÞÀ©¡¢¿´ÉÔÀ°Ì®¡¢ºª¿ç¡¢¤ª¤è¤Ó»à¤ò°ú¤­µ¯¤³¤¹²ÄǽÀ­¤¬¤¢¤ê¤Þ¤¹¡£

¡Ê¤³¤Î¹à¤Î°Ê¹ß¤ÎÍ×Ìó¡Ë
¾¤Î°åÌôÉʤȤÎÊ»ÍѤÏÈò¤±¤Æ²¼¤µ¤¤¡£ÆÃ¤Ë¿Õµ¡Ç½ÉÔÁ´¤Î´µ¼Ô¡Ê¥¯¥ì¥¢¥Á¥Ë¥ó¥¯¥ê¥¢¥é¥ó¥¹¡§Ëèʬ30mL¡ÊËèÉÃ0.50mL¡Ë̤Ëþ¡Ë¤Ï¡¢Àݼè¤ò¤·¤Ê¤¤¤Ç¤¯¤À¤µ¤¤¡£


Conclusions
·ëÏÀ

Magnesium is an essential electrolyte for living organisms. Magnesium intoxication is rare. A magnesium deficiency is associated with a variety of diseases. In humans, a magnesium deficiency is associated with cardiovascular diseases, e.g., hypertension, pre-eclampsia, arrhythmias, heart failure. Arteriosclerosis, diabetes mellitus, and metabolic syndrome often occur in magnesium deficient humans. Furthermore, neurological symptoms are strengthened in magnesium deficient patients. Magnesium supplementation in those patients can be of benefit in most cases.

¥Þ¥°¥Í¥·¥¦¥à¤ÏÀ¸Êª¤Ë¤È¤Ã¤ÆÉ¬¿Ü¤ÎÅŲò¼Á¤Ç¤¹¡£ ¥Þ¥°¥Í¥·¥¦¥àÃæÆÇ¤Ï¤Þ¤ì¤Ç¤¹¡£ ¥Þ¥°¥Í¥·¥¦¥à·ç˳¾É¤Ï¤µ¤Þ¤¶¤Þ¤Êɵ¤¤Ë´ØÏ¢¤·¤Æ¤¤¤Þ¤¹¡£ 

¥Ò¥È¤Ç¤Ï¡¢¥Þ¥°¥Í¥·¥¦¥à·ç˳¾É¤Ï¿´·ì´É¼À´µ¡¢Î㤨¤Ð¹â·ì°µ¡¢»ÒáòÁ°¾É¡¢ÉÔÀ°Ì®¡¢¿´ÉÔÁ´¤È´ØÏ¢¤·¤Æ¤¤¤Þ¤¹¡£ ư̮¹Å²½¾É¡¢¿¿À­ÅüǢɡ¢¤ª¤è¤Ó¥á¥¿¥Ü¥ê¥Ã¥¯¥·¥ó¥É¥í¡¼¥à¡ÊÃ𣱣´¡Ë¤Ï¡¢¥Þ¥°¥Í¥·¥¦¥à·ç˳¤Î¥Ò¥È¤Ç¤·¤Ð¤·¤Ðµ¯¤³¤ê¤Þ¤¹¡£

¡ÊÃ𣱣´¡Ë¥á¥¿¥Ü¥ê¥Ã¥¯¥·¥ó¥É¥í¡¼¥à
Æâ¡»éË÷¿ÈîËþ¡ÊÆâ¡ÈîËþ¡¦Ê¢ÉôÈîËþ¡Ë¤Ë¹â·ìÅü¡¦¹â·ì°µ¡¦»é¼Á°Û¾ï¾É¤Î¤¦¤Á2¤Ä°Ê¾å¤Î¾É¾õ¤¬°ìÅ٤˽ФƤ¤¤ë¾õÂÖ¤ò¤¤¤¦¡£

 ¤µ¤é¤Ë¡¢¿À·Ð³ØÅª¾É¾õ¤Ï¥Þ¥°¥Í¥·¥¦¥à·ç˳´µ¼Ô¤Ç¶¯²½¤µ¤ì¤Æ¤¤¤Þ¤¹¡£ ¤³¤ì¤é¤Î´µ¼Ô¤µ¤ó¤Ø¤Î¥Þ¥°¥Í¥·¥¦¥àÊäµë¤Ï¡¢¤Û¤È¤ó¤É¤Î¾ì¹çÍ­±×¤Ç¤¹¡£
¡Ê°Ê²¼¾Êά¡Ë

¡Ê¥½¡¼¥¹¡Ë



¡ØÆÍÁ³»àÂкö¡§¥Þ¥°¥Í¥·¥¦¥à¡Ù¡¡2018/11/28(¿å) 
¡ØÍ½Ëɤȼ£ÎŤΥޥ°¥Í¥·¥¦¥à¡Ù¡¡2018/12/5(¿å) 
Magnesium in Prevention and Therapy
£í




¡Ö¢£°û¿©Êª¤Î¥ê¥¹¥¯¤ÈÂкö¡×½ñ¸Ë¤Îµ­»ö°ìÍ÷

ÊĤ¸¤ë ¥³¥á¥ó¥È¡Ê1¡Ë

¥¢¥Ð¥¿¡¼

2019/1/25(¶â)¤ÎÆâ½ï¤µ¤ó¡¢º£¡¢Ä´¤Ù¤Þ¤·¤¿¤é¡¢µþÅԻԤΡÚÍ×¶ÛµÞ°ÂÁ´³ÎǧÂ絬ÌÏ·úÃÛʪ¤ÎÂѿ̿ÇÃÇ·ë²Ì¡Û¡Ê£²£°£±£·Ç¯¡Ë¤Ë¤è¤ë¤ÈÂѿ̤ˤʤäƤ¤¤ë¤è¤¦¤Ç¤¹¡£
http://www.city.kyoto.lg.jp/tokei/cmsfiles/contents/0000216/216560/shindan290828.pdf

2019/1/27(Æü) ¸áÁ° 2:15 ¿å̵À¥¤è¤ê


.
¥¢¥Ð¥¿¡¼
¿å̵À¥¤è¤ê
Èó¸ø³« / Èó¸ø³«
¿Íµ¤ÅÙ
Yahoo!¥Ö¥í¥°¥Ø¥ë¥× - ¥Ö¥í¥°¿Íµ¤Å٤ˤĤ¤¤Æ
Æü ·î ²Ð ¿å ÌÚ ¶â ÅÚ
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

¥Ö¥í¥°¥Ð¥Ê¡¼

Yahoo!¤«¤é¤Î¤ªÃΤ餻

¸¡º÷ ¸¡º÷

²áµî¤Îµ­»ö°ìÍ÷

¥¹¥Þ¡¼¥È¥Õ¥©¥ó¤Ç¸«¤ë

¥â¥Ð¥¤¥ëÈÇYahoo!¥Ö¥í¥°¤Ë¥¢¥¯¥»¥¹¡ª

¥¹¥Þ¡¼¥È¥Õ¥©¥óÈÇYahoo!¥Ö¥í¥°¤Ë¥¢¥¯¥»¥¹¡ª

ɸ½à¥°¥ë¡¼¥×

¤è¤·¤â¤È¥Ö¥í¥°¥é¥ó¥­¥ó¥°

¤â¤Ã¤È¸«¤ë

¤ß¤ó¤Ê¤Î¹¹¿·µ­»ö